Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 216.30
LCI's Cash to Debt is ranked higher than
73% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.03 vs. LCI: 216.30 )
Ranked among companies with meaningful Cash to Debt only.
LCI' s 10-Year Cash to Debt Range
Min: 0.01   Max: N/A
Current: 216.3

Equity to Asset 0.92
LCI's Equity to Asset is ranked higher than
97% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.43 vs. LCI: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
LCI' s 10-Year Equity to Asset Range
Min: -0.17   Max: 0.92
Current: 0.92

-0.17
0.92
Interest Coverage 677.61
LCI's Interest Coverage is ranked higher than
77% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. LCI: 677.61 )
Ranked among companies with meaningful Interest Coverage only.
LCI' s 10-Year Interest Coverage Range
Min: 1.54   Max: 677.61
Current: 677.61

1.54
677.61
F-Score: 6
Z-Score: 37.13
M-Score: -1.92
WACC vs ROIC
21.95%
79.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 54.83
LCI's Operating margin (%) is ranked higher than
99% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. LCI: 54.83 )
Ranked among companies with meaningful Operating margin (%) only.
LCI' s 10-Year Operating margin (%) Range
Min: -119.46   Max: 46.27
Current: 54.83

-119.46
46.27
Net-margin (%) 35.94
LCI's Net-margin (%) is ranked higher than
97% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.76 vs. LCI: 35.94 )
Ranked among companies with meaningful Net-margin (%) only.
LCI' s 10-Year Net-margin (%) Range
Min: -73   Max: 28.64
Current: 35.94

-73
28.64
ROE (%) 40.99
LCI's ROE (%) is ranked higher than
96% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.48 vs. LCI: 40.99 )
Ranked among companies with meaningful ROE (%) only.
LCI' s 10-Year ROE (%) Range
Min: -38.23   Max: 117.18
Current: 40.99

-38.23
117.18
ROA (%) 36.50
LCI's ROA (%) is ranked higher than
98% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. LCI: 36.50 )
Ranked among companies with meaningful ROA (%) only.
LCI' s 10-Year ROA (%) Range
Min: -28.9   Max: 50.98
Current: 36.5

-28.9
50.98
ROC (Joel Greenblatt) (%) 132.82
LCI's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.04 vs. LCI: 132.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -162.82   Max: 107.31
Current: 132.82

-162.82
107.31
Revenue Growth (3Y)(%) 24.90
LCI's Revenue Growth (3Y)(%) is ranked higher than
91% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.40 vs. LCI: 24.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LCI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.6   Max: 48.4
Current: 24.9

-3.6
48.4
EBITDA Growth (3Y)(%) 152.30
LCI's EBITDA Growth (3Y)(%) is ranked higher than
100% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -31.90 vs. LCI: 152.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LCI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 152.3
Current: 152.3

0
152.3
» LCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

LCI Guru Trades in Q2 2014

Joel Greenblatt 35,709 sh (New)
Chuck Royce 338,400 sh (New)
Jim Simons Sold Out
» More
Q3 2014

LCI Guru Trades in Q3 2014

Paul Tudor Jones 28,221 sh (New)
Joel Greenblatt 303,345 sh (+749.49%)
Chuck Royce 427,410 sh (+26.30%)
» More
Q4 2014

LCI Guru Trades in Q4 2014

Joel Greenblatt 1,026,029 sh (+238.24%)
Chuck Royce 499,830 sh (+16.94%)
Paul Tudor Jones 31,436 sh (+11.39%)
» More
Q1 2015

LCI Guru Trades in Q1 2015

Steven Cohen 65,000 sh (New)
Joel Greenblatt 1,555,795 sh (+51.63%)
Paul Tudor Jones 12,958 sh (-58.78%)
Chuck Royce 155,480 sh (-68.89%)
» More
» Details

Insider Trades

Latest Guru Trades with LCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 14.90
LCI's P/E(ttm) is ranked higher than
84% of the 530 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.90 vs. LCI: 14.90 )
Ranked among companies with meaningful P/E(ttm) only.
LCI' s 10-Year P/E(ttm) Range
Min: 12.33   Max: 185.79
Current: 14.9

12.33
185.79
Forward P/E 15.24
LCI's Forward P/E is ranked higher than
73% of the 426 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.96 vs. LCI: 15.24 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 14.70
LCI's PE(NRI) is ranked higher than
83% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.70 vs. LCI: 14.70 )
Ranked among companies with meaningful PE(NRI) only.
LCI' s 10-Year PE(NRI) Range
Min: 12.32   Max: 222.5
Current: 14.7

12.32
222.5
P/B 4.60
LCI's P/B is ranked lower than
61% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. LCI: 4.60 )
Ranked among companies with meaningful P/B only.
LCI' s 10-Year P/B Range
Min: 0.61   Max: 6.39
Current: 4.6

0.61
6.39
P/S 5.30
LCI's P/S is ranked lower than
81% of the 830 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. LCI: 5.30 )
Ranked among companies with meaningful P/S only.
LCI' s 10-Year P/S Range
Min: 0.49   Max: 7.09
Current: 5.3

0.49
7.09
PFCF 22.50
LCI's PFCF is ranked higher than
70% of the 438 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.02 vs. LCI: 22.50 )
Ranked among companies with meaningful PFCF only.
LCI' s 10-Year PFCF Range
Min: 3.21   Max: 342.5
Current: 22.5

3.21
342.5
POCF 17.26
LCI's POCF is ranked higher than
65% of the 444 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.56 vs. LCI: 17.26 )
Ranked among companies with meaningful POCF only.
LCI' s 10-Year POCF Range
Min: 2.86   Max: 577
Current: 17.26

2.86
577
EV-to-EBIT 8.38
LCI's EV-to-EBIT is ranked higher than
92% of the 471 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.90 vs. LCI: 8.38 )
Ranked among companies with meaningful EV-to-EBIT only.
LCI' s 10-Year EV-to-EBIT Range
Min: -114.7   Max: 687.5
Current: 8.38

-114.7
687.5
PEG 0.50
LCI's PEG is ranked higher than
92% of the 246 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. LCI: 0.50 )
Ranked among companies with meaningful PEG only.
LCI' s 10-Year PEG Range
Min: 0.15   Max: 77.25
Current: 0.5

0.15
77.25
Shiller P/E 56.00
LCI's Shiller P/E is ranked lower than
68% of the 414 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.08 vs. LCI: 56.00 )
Ranked among companies with meaningful Shiller P/E only.
LCI' s 10-Year Shiller P/E Range
Min: 21.37   Max: 358
Current: 56

21.37
358
Current Ratio 10.52
LCI's Current Ratio is ranked higher than
90% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. LCI: 10.52 )
Ranked among companies with meaningful Current Ratio only.
LCI' s 10-Year Current Ratio Range
Min: 0.99   Max: 10.52
Current: 10.52

0.99
10.52
Quick Ratio 9.30
LCI's Quick Ratio is ranked higher than
90% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. LCI: 9.30 )
Ranked among companies with meaningful Quick Ratio only.
LCI' s 10-Year Quick Ratio Range
Min: 0.26   Max: 9.3
Current: 9.3

0.26
9.3
Days Inventory 160.70
LCI's Days Inventory is ranked lower than
71% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.86 vs. LCI: 160.70 )
Ranked among companies with meaningful Days Inventory only.
LCI' s 10-Year Days Inventory Range
Min: 68.82   Max: 174.73
Current: 160.7

68.82
174.73
Days Sales Outstanding 74.95
LCI's Days Sales Outstanding is ranked lower than
52% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.43 vs. LCI: 74.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
LCI' s 10-Year Days Sales Outstanding Range
Min: 34.69   Max: 171.98
Current: 74.95

34.69
171.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.60
LCI's Price/Net Cash is ranked higher than
55% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.30 vs. LCI: 10.60 )
Ranked among companies with meaningful Price/Net Cash only.
LCI' s 10-Year Price/Net Cash Range
Min: 10.91   Max: 42.78
Current: 10.6

10.91
42.78
Price/Net Current Asset Value 7.40
LCI's Price/Net Current Asset Value is ranked higher than
65% of the 408 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.00 vs. LCI: 7.40 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
LCI' s 10-Year Price/Net Current Asset Value Range
Min: 2.02   Max: 91.68
Current: 7.4

2.02
91.68
Price/Tangible Book 4.70
LCI's Price/Tangible Book is ranked lower than
51% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. LCI: 4.70 )
Ranked among companies with meaningful Price/Tangible Book only.
LCI' s 10-Year Price/Tangible Book Range
Min: 0.9   Max: 21.7
Current: 4.7

0.9
21.7
Price/DCF (Projected) 3.60
LCI's Price/DCF (Projected) is ranked lower than
54% of the 485 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. LCI: 3.60 )
Ranked among companies with meaningful Price/DCF (Projected) only.
LCI' s 10-Year Price/DCF (Projected) Range
Min: 0.57   Max: 5.86
Current: 3.6

0.57
5.86
Price/Median PS Value 3.30
LCI's Price/Median PS Value is ranked lower than
87% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. LCI: 3.30 )
Ranked among companies with meaningful Price/Median PS Value only.
LCI' s 10-Year Price/Median PS Value Range
Min: 0.42   Max: 6.89
Current: 3.3

0.42
6.89
Price/Peter Lynch Fair Value 0.60
LCI's Price/Peter Lynch Fair Value is ranked higher than
95% of the 224 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.50 vs. LCI: 0.60 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
LCI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.5   Max: 15.96
Current: 0.6

0.5
15.96
Price/Graham Number 1.70
LCI's Price/Graham Number is ranked higher than
69% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. LCI: 1.70 )
Ranked among companies with meaningful Price/Graham Number only.
LCI' s 10-Year Price/Graham Number Range
Min: 0.93   Max: 6.23
Current: 1.7

0.93
6.23
Earnings Yield (Greenblatt) 11.70
LCI's Earnings Yield (Greenblatt) is ranked higher than
93% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.00 vs. LCI: 11.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
LCI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 14.4
Current: 11.7

0.1
14.4
Forward Rate of Return (Yacktman) 76.69
LCI's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.59 vs. LCI: 76.69 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
LCI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -15   Max: 115.5
Current: 76.69

-15
115.5

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 405 443 507 549
EPS($) 3.96 3.63 3.71 3.84
EPS without NRI($) 3.96 3.63 3.71 3.84

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:LN5.Germany,
Lannett Co Inc was incorporated in 1942 under the laws of the Commonwealth of Pennsylvania, and reincorporated in 1991 as a Delaware corporation. The Company develops, manufactures, markets and distributes generic versions of branded pharmaceutical products. The Company manufactures solid oral dosage forms, including tablets and capsules, extended release, topicals, oral solutions and distributes parenteral as well as ophthalmics. All of the products are currently manufactured and sold are prescription products. The Company's products containing Levo are produced and marketed with 12 varying potencies. In addition to generic Levo tablets, it also market and distribute Unithroid tablets, a branded version of Levo, which is produced and marketed with 11 varying potencies. Both generic Levo tablets and Unithroid tablets are manufactured by JSP. Lannett began buying generic Levo from JSP and selling it to its customers in April 2003. Levo tablets are used to treat hypothyroidism and other thyroid disorders. Levo remains the most prescribed drugs in the U.S. and is used by over 13 million patients of various ages and demographic backgrounds. In distribution of these products, the Company competes with two branded Levo products-Abbott Laboratories Synthroid(r) and Monarch Pharmaceuticals Levoxyl(r)- as well as generic products from Mylan and Sandoz. Digoxin tablets are produced and marketed with two different potencies, 0.125mg and 0.25mg per tablet. This product is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in September 2002. Digoxin tablets are used to treat congestive heart failure in patients of various ages and demographic backgrounds. The Company distributes two products containing Butalbital. Lannett has manufactured and sold one of the products, Butalbital with Aspirin and Caffeine capsules, for more than nine years. The other Butalbital product, Butalbital with Aspirin, Caffeine and Codeine Phosphate capsules, is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in December 2002. Both Butalbital products, which are in orally administered capsule dosage forms, are prescribed to treat tension headaches caused by contractions of the muscles in the neck and shoulder area and migraine. Primidone tablets are produced and marketed with two different potencies, 50mg and 250mg tablets. Lannett has developed and manufacture Primidone tablets and began selling Primidone 50mg tablets in June 2001. In addition, the Company has been manufacturing and selling Primidone 250mg tablets for more than seven years. Both Primidone products, which are in orally administered tablet dosage forms, are prescribed to treat convulsion and seizures in epileptic patients of all ages and demographic backgrounds. Lannett sell its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, ma
» More Articles for LCI

Headlines

Articles On GuruFocus.com
misc Apr 18 2015 
Pharmaceutical Stock Picks For March Mar 04 2015 
My Stocks Feb 13 2015 
My Stocks Feb 13 2015 
Lannett Company Looks Cheap At First Glance; But It Is Actually Much Cheaper Than It Looks Dec 29 2014 
comment on LCI Nov 19 2012 
comment on LCI Nov 13 2012 
comment on LCI Jan 26 2012 
comment on LCI Jan 26 2012 
comment on LCI Jan 23 2012 

More From Other Websites
Regeneron, Lannett Among The 4 Top-Rated Drug Stocks May 28 2015
Lightning Round: This is a one way ticket down May 21 2015
Lannett (LCI) Signs Deal to Acquire Silarx Pharmaceuticals - Analyst Blog May 19 2015
Celgene, Lannett Lead Boisterous Day For Drugmakers May 18 2015
LANNETT CO INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... May 18 2015
Lannett Signs Definitive Agreement To Acquire Silarx Pharmaceuticals, Inc. May 18 2015
LANNETT CO INC Financials May 15 2015
10-Q for Lannett Co., Inc. May 11 2015
LANNETT CO INC Files SEC form 10-Q, Quarterly Report May 08 2015
IBD Market Wrap - 05/07/15 May 07 2015
LANNETT CO INC Files SEC form 8-K, Results of Operations and Financial Condition May 07 2015
Lannett beats 3Q profit forecasts May 06 2015
Lannett beats 3Q profit forecasts May 06 2015
Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results May 06 2015
Q3 2015 Lannett Company Inc Earnings Release - After Market Close May 06 2015
Lannett To Report Fiscal 2015 Third-Quarter Financial Results And Host Conference Call On Wednesday,... Apr 30 2015
3 Mid-Cap Pharmaceutical Companies to Add to Your Portfolio Apr 28 2015
LANNETT CO INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Apr 24 2015
Lannett Expands Revolving Credit Facility To $120 Million Apr 24 2015
Stop Worrying About A Correction And Do This Apr 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK